Enhanced Pain Management Following Rotator Cuff Repair: Interscalene Block with Intravenous Dexamethasone

Enhanced Pain Management Following Rotator Cuff Repair: Interscalene Block with Intravenous Dexamethasone

This research investigated whether intravenous dexamethasone added to an interscalene block (a standard method of pain control for shoulder surgery) would be better than the block alone for controlling pain after rotator cuff repair surgery. Rotator cuff surgery is likely to produce intense postoperative pain, and good methods of alleviating this pain are needed. Interscalene blocks are good for the relief of pain for a limited time, but they have rebound pain, and their action is not prolonged and needs to be supplemented.

Exploring Targeted-Release Budesonide for IgA Nephropathy: A Comprehensive Review

Exploring Targeted-Release Budesonide for IgA Nephropathy: A Comprehensive Review

The article discusses the potential use of targeted-release budesonide (TRF-budesonide) in treating IgA nephropathy (IgAN), a common kidney disease characterized by IgA deposits in the kidneys. IgAN can lead to end-stage renal disease, and current treatments like ACE inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) aren’t always effective in slowing disease progression.

Merilog Becomes First FDA-Approved Rapid-Acting Insulin Biosimilar for Diabetes Care

Merilog Becomes First FDA-Approved Rapid-Acting Insulin Biosimilar for Diabetes Care

The U.S. Food and Drug Administration (FDA) has approved Merilog (insulin-aspart-szjj), a Novolog (insulin aspart) biosimilar, for the control of glycemia in adults and pediatric patients with diabetes mellitus. Merilog is the first FDA-approved rapid-acting insulin biosimilar and is available as a 3 mL prefilled pen and a 10 mL multiple-dose vial. Merilog reduces mealtime blood sugar surges, allowing for improved control of diabetes.